

F2B
Cmt
SUB M22
Cmt

L-lysine, sulfatidic acid or fatty acids.

Please add the following claims.

sub Q35 --232. The composition of claim 108, which comprises particle sizes of about 0.5 μ to about 10 μ or about 10 μ to about 500 μ .

233. The nucleic acid of claim 108, which is operatively linked to a vector.

234. (Amended) A single cell, comprising the nucleic acid of claim 233. --

F24

SUB M23

REMARKS

THE INTERVIEW

Dr. Epps is hereby thanked for agreeing to hold an interview on March 22, 2001, and for her further comments of March 27, 2001. During the course of the interview, the applicant's attorney faxed proposed amendments prior to the interview, during which the various issues remaining were discussed. Agreement was reached on claim language and the amendments to the specification and the Sequence Listing. The following remarks contain the substance of the arguments exchanged during the interview and an expansion thereof.

THE PENDING CLAIMS

Claims 108-131, 133-134, 146, 148, 151-156, 158-159, 161-173, 175-176, 178-181, 183-193, 195-198 and 200-231 were pending, claims 176 and 190 have been deleted, claims 232-234 added, and various claims amended. Accordingly, Claims 108-131, 133-134, 146, 148, 151-156, 158-159, 161-173, 175, 178-181, 183-189, 191-193, 195-198 and 200-234 remain pending in this case. The applicant requests reconsideration of the rejections and allowance of the pending claims in view of the above amendments and the agreement reached during the interview.

THE SEQUENCE LISTING

A Substitute Sequence Listing is being couriered to the examiner, who is requested to substitute it for that filed May 4, 2000. A Declaration is also enclosed.

SERIAL NO: 08/093,972

PATENT

THE SPECIFICATION

The applicant has delete language relating to sequences and certain targets that were objected to.

THE CLAIMS

The claims have been amended as agreed to during the interview and, therefore, believed to be in allowable form.

GENERAL REMARKS

The Assistant Commissioner is hereby authorized to charge payment of a fee for a two-month extension of time for \$195.-, as well as any other owed, to Deposit Account No. 50-1278. No fee is believed owed for the added claims.

In view of the foregoing amendments and remarks, and of the filing (by courier) of a Substitute Sequence Listing and Declaration, as well as a Petition for Extension of Time with payment of the requisite fee, this application is believed to be in condition for examination and allowance. Early notice to this respect is solicited.

Respectfully submitted.
EPIGENESIS PHARMACEUTICALS, INC



Viviana Amzel, Ph. D.
Reg. No. 30930
Attorney for Applicant(s)

March 28, 2001

Date

7 Clarke Drive
Cranbury, NJ 08512
609-409-3035 Ph.
413-845-7530 Fax
Vamzel@epigene.com